DoW Autism Clinical Trial Award

The Autism Research Program Clinical Trial Award is administered by the Defense Health Agency through the Congressionally Directed Medical Research Programs, a federal funding initiative established to support high-impact biomedical research. The program is part of a broader congressional effort to improve the lives of individuals with autism and their families through targeted scientific investment. Since its inception in 2007, the Autism Research Program has allocated substantial funding toward innovative research, and this specific award mechanism focuses on advancing clinical trials that can rapidly translate into meaningful interventions or improvements in care. The purpose of this funding opportunity is to support the execution and analysis of clinical trials that demonstrate strong potential to significantly impact the treatment or management of autism. Projects funded under this mechanism may range from early-stage proof-of-concept studies to large-scale trials evaluating efficacy in defined patient populations. The program encourages research that aligns with designated areas of interest, such as improving access to care, enhancing quality of life, advancing therapeutic interventions, and addressing health disparities, including those affecting military families and aging autistic populations. Applicants are expected to demonstrate how their proposed research addresses these priorities or otherwise contributes meaningfully to the field. Funding under this opportunity is limited, with approximately 3.25 million dollars expected to be allocated across two awards. A standard Clinical Trial Award has a maximum total cost of 1.5 million dollars, while a higher funding tier of up to 1.75 million dollars is available for projects that include a partnership between an experienced investigator and an early-career researcher. The maximum period of performance is four years. Allowable costs include direct and indirect expenses necessary to conduct the clinical trial, such as participant compensation, travel for collaboration, and dissemination of results. Preclinical research is explicitly excluded, and all funded projects must involve clinical trials. Eligibility for this funding opportunity is broad, encompassing both domestic and international organizations, including academic institutions, industry entities, nonprofit organizations, and government agencies. Principal Investigators must meet specific criteria depending on the application type. For single-investigator applications, the PI must hold a position equivalent to Assistant Professor or higher. For the partnering investigator option, the early-career investigator must be within seven years of completing their terminal degree and must contribute at least 50 percent effort to the project. Applications must also include meaningful collaboration with community stakeholders, such as autistic individuals or caregivers, who will contribute throughout the research process. The application process is structured in two stages. First, applicants must submit a pre-application through the Electronic Biomedical Research Application Portal, which includes a narrative describing the research concept, intervention, and anticipated impact. Selected applicants will then be invited to submit a full application through Grants.gov or eBRAP, depending on organizational affiliation. The full application requires extensive documentation, including a detailed project narrative, intervention plan, recruitment strategy, regulatory documentation, and multiple supporting attachments. Strict compliance with submission requirements is mandatory, and incomplete applications will be rejected. Applications undergo a rigorous two-tier review process. The first tier is peer review, which evaluates scientific merit, feasibility, study design, and potential impact. The second tier is programmatic review, which considers alignment with program priorities and overall portfolio balance. Key evaluation criteria include the strength of the research strategy, the appropriateness of the intervention, the feasibility of recruitment and retention plans, and the anticipated clinical impact. Additional emphasis is placed on ethical considerations, statistical rigor, and the integration of community collaboration. The timeline for this funding opportunity includes a pre-application deadline of July 27, 2026, followed by an invitation to submit full applications by August 28, 2026. Full applications are due by October 22, 2026, with peer review occurring in December 2026 and programmatic review in February 2027. Awards are expected to be made by September 30, 2027. Applicants must ensure active registrations in required federal systems prior to submission, and technical assistance is available through designated help desks.

Emphasize strong preliminary data, clear clinical impact, and integrated community collaboration; ensure feasibility of recruitment and regulatory readiness